OpenEvidence Hits 1 Million AI-Assisted Clinical Consultations in a Single Day

New updates have been reported about OpenEvidence.

OpenEvidence has reached a major adoption milestone, recording one million clinical consultations between NPI-verified physicians and its medical AI platform within a single 24-hour period on March 10, 2026. The company’s CEO, Daniel Nadler, described the event as a tipping point where AI shifts from experimental support to a trusted, embedded partner in high-stakes clinical decision-making.

At the core of OpenEvidence’s strategy is strict reliance on peer-reviewed medical literature, with answers sourced and cited from leading publications and guideline bodies such as the New England Journal of Medicine, JAMA, the National Comprehensive Cancer Network, and the Cochrane Library. This evidence-first design has driven rapid penetration, with the platform now used daily by a majority of practicing physicians in the United States, positioning OpenEvidence as a critical infrastructure layer in clinical workflows.

Nadler emphasized that each consultation represents a real-time clinical decision where physicians seek fast and accurate guidance for patient care, framing the one-day volume as one million instances of potentially improved outcomes and reduced decision latency. This usage scale underscores the company’s operational capacity to support high volumes of concurrent, regulated clinical interactions while maintaining compliance requirements, including a secure, HIPAA-compliant environment.

OpenEvidence is widely recognized as one of the leading medical AI tools, with the New England Journal of Medicine JW labeling it “the best AI tool for medical information,” and independent studies indicating that more American doctors use OpenEvidence than all other AI systems combined. Supported by major investors such as Google, Nvidia, and Sequoia, the company describes itself as the most valuable doctor-technology platform globally, signaling strong capital backing and expectations for continued expansion.

Strategically, this milestone validates OpenEvidence’s product-market fit in clinical decision support and strengthens its bargaining power with health systems, payers, and content partners. At the same time, the surge in physician usage may create additional opportunities for data-driven product enhancements, integration into electronic health records, and broader commercialization across specialties and care settings.

Looking ahead, sustained daily use at this scale could entrench OpenEvidence as a default decision-support layer in U.S. healthcare, while also providing a proof point for future international growth. For executives and investors, the million-consultations-in-a-day benchmark illustrates both the readiness of clinicians to rely on AI in routine care and the company’s potential to shape standards for evidence-based, AI-assisted medicine over the medium term.